10x Genomics (TXG) said Wednesday it reached a settlement agreement with Bruker (BRKR) to resolve all worldwide patent litigation and disputes between the two companies.
As part of the deal, Bruker will pay $68 million to 10x Genomics in equal quarterly installments from Q3 of 2025 through Q2 of 2026, along with ongoing royalties on sales of its spatial biology products for the duration of the licensed patents, according to 10x Genomics.
Shares of 10x Genomics were up 1.5% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.